Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus chemotherapy as first-line treatment for HER2-mutant advanced non-small cell lung cancer
ChiCTR2100045460Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyrotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Started Mar 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100045460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045460.